NCT07134439Not yet recruiting
Identifying Fundamental Mechanisms of Skeletal Muscle Ageing in Older Men Undergoing Androgen Deprivation Therapy: a Feasibility Study
Source: ClinicalTrials.gov · Last updated 21 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
To find out whether it is possible to run a study looking at the underlying markers of ageing in muscle quality and quantity in men receiving Androgen Deprivation Therapy for prostate cancer treatment. To determine the feasibility of conducting an observational study examining the association of fundamental biological markers of ageing with changes in body composition and skeletal muscle morphology following ADT in older men undergoing prostate cancer treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 14 Aug 2025
- Start date
- Sept 2025
- Primary completion date
- Jun 2026
- Lead sponsor
- Guy's and St Thomas' NHS Foundation Trust
- Diseases
- Prostate cancer
- NCT number
- NCT07134439
What you commit to
- Study type: Observational
- Planned participants: 20
- From Sept 2025 to the primary completion date, Jun 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Systemic anti-cancer therapy within one year of recruitment (for prostate cancer or any other concomitant cancer)
- Planned surgery (not including eye surgery or other minor surgery) within six months of ADT
- Any other condition previous or current which, in the judgement of the responsible clinician, is likely to interfere with the trial / assessments.
- On treatment with clopidogrel, high-dose aspirin, dipyridamole or anticoagulants
Lab values
- Known bleeding disorder or platelets \<75x103/mL
Other
- Lacks capacity to consent
Who the study is looking for
- Age ≥65 years old at time of recruitment
- Able to provide informed consent to participate
- Known prostate cancer due to be initiated on ADT for the first time (with or without Androgen Receptor Targeted Agents (ARTA) or radiotherapy), or initiated within two weeks prior to recruitment.
- Individuals involved in other research will be eligible to participate so long as the other research does not involve potential changes to the standard ADT care the participant will be receiving and does not involve an intervention aimed at reducing the muscle atrophy associated with ADT.
Age in the registry: 65 years to - · Sex: Male · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.